Medplus Health Services announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its store locations. The suspensions, issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, are expected to result in a potential revenue loss of approximately Rs 4.06 lacs.

Suspension Details

The company disclosed the following details regarding the suspensions:

Bilaspur, Chhattisgarh Store

• Location: Swarnplaza, Bilaspur
• Issuing Authority: Assistant Drugs Controller, Bilaspur District, Chhattisgarh
• Duration: Five days
• Potential Revenue Loss: Rs 4.00 lacs

Mahabubnagar, Telangana Store

• Location: Shankarayapally Jadcherla
• Issuing Authority: Assistant Director, Drugs Control Administration, Mahabubnagar, Telangana
• Duration: Four days
• Potential Revenue Loss: Rs 0.06 lacs

Regulatory Compliance

Medplus Health Services reported this development in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also adhered to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Impact and Disclosure

The total potential revenue impact from these suspensions is estimated at Rs 4.06 lacs. MedPlus has stated that this information will be available on the company's website as well as on the websites of BSE Limited and National Stock Exchange of India Ltd.

The suspension orders were received on September 17, and the company made the disclosure to the stock exchanges on September 18, demonstrating prompt communication with its stakeholders.

Investors and stakeholders are advised to monitor further updates from the company regarding the resolution of these suspensions and any potential long-term impacts on the company's operations.

Medplus Health Services Limited , a prominent player in the Indian pharmacy retail sector, has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its stores in Telangana. The company made this announcement in a regulatory filing to the stock exchanges on September 9, 2025.

Suspension Details

The Assistant Director of Drugs Control Administration, Secunderabad, issued the suspension orders on September 8, 2025, affecting two stores:

1. West Marredpally Circle store: Suspended for one day
2. Vijayapuri Colony South Lalaguda Road store: Suspended for four days

These suspensions were imposed under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

Medplus has estimated the potential revenue losses from these suspensions:

Regulatory Compliance

The company has made this disclosure in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, MedPlus has adhered to the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Transparency Measures

MedPlus has stated that the details of this matter will be available on the company's website ( www.medplusindia.com ) as well as on the websites of BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Ltd. ( www.nseindia.com ).

While the immediate financial impact appears limited, this incident highlights the regulatory challenges faced by pharmacy retail chains in India and the importance of maintaining compliance with drug licensing regulations.